Cybin Corp announces a CAD$20 million financing at a unit price of CAD$2.25.
Exploring the companies and themes that make up this emerging and exciting new sector
Peter Thiel-backed psychedelics start-up targets schizophrenia ahead of IPO
LONDON — ATAI Life Science, a Peter Thiel-backed start-up, has taken a majority stake in Recognify, a company that is developing drugs to help treat schizophrenia.
Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units
Mydecine announces a bought-deal financing with units priced at CAD$0.50.
Researchers believe 'magic' mushrooms have the potential to curb obesity
Researchers have started to explore the potential for psilocybin, the psychedelic drug found in "magic" mushrooms, to treat obesity.
UFC looks into Johns Hopkins study on psychedelic drugs as potential therapy for fighters
The UFC is looking to get involved with research into psychedelic drugs as a therapy for fighters' brain health.
MindMed Adds Chief Development Officer with FDA Phase 2 Psilocybin Clinical Trial Experience
NEW YORK, Jan. 14, 2021 /PRNewswire/ -- MindMed (NEO: MMED), (OTCQB: MMEDF), (DE: MMQ), a leading psychedelic medicine biotech company today announced the addition of Robert Barrow, an accomplished pharmaceutical executive, as Chief Development Officer.
Novamind Expands Psychedelic Medicine Access in Utah
Novamind Inc announces the expansion and optimization of its Cedar Psychiatry clinic in Utah.
This is Why the Psilocybin Story is Quickly Gaining Momentum
Clinical studies continue to support the use of psilocybin for mental health. For example, a study from JAMA Psychiatry found that psilocybin “worked better than the usual antidepressant medications,” as noted by NPR.
ATAI or MindMed: Which Is The Better Opportunity?
ATAI Life Sciences and MindMed Inc have the deepest psychedelics operations in this sector. Which is the better opportunity?
Mind Cure Signs LOI to Acquire an Ownership Interest in Psychedelic Treatment Center ATMA, Selected by Section 56 Exempt Patient for Psilocybin Therapy
MindCure signs LOI to make a strategic investment in ATMA, a psychedelics-assisted therapy center in Calgary, Alberta.
Cybin Announces API Synthesis of Multiple Tryptamine Derivatives Based on the First Milestone Achievement Pursuant to the Adelia Acquisition
Cybin announces the API synthesis of multiple tryptamine derivatives.
MindMed Expands Psychedelic Microdosing Division, Adds Groundbreaking Study Evaluating LSD Microdosing Through Next-Gen Digital Clinical Markers
MindMed commences LSD microdosing study on various health-and-wellness benefits.